Document
DailyMed Label: Lidocan
Title
DailyMed Label: Lidocan
Date
2023
Document type
DailyMed Prescription
Name
Lidocan
Generic name
Lidocaine 5%
Manufacturer
PURETEK CORPORATION
Product information
NDC: 59088-905
Product information
NDC: 59088-905
Description
LIDOCAN™ is comprised of an adhesive material containing 5% lidocaine, which is applied to a non-woven polyester felt backing and covered with a polyethylene terephthalate (PET) film release liner. The release liner is removed prior to application to the skin. The size of the patch is 10 cm x 14 cm.
Lidocaine is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl), has an octanol:water partition ratio of 43 at pH 7.4, and has the following structure:
Each adhesive patch contains 700 mg of lidocaine (50 mg per gram adhesive) in an aqueous base. It also contains the following inactive ingredients: purified water, glycerin, sorbitol, polyacrylic acid, sodium carboxymethylcellulose, sodium polyacrylate, propylene glycol, urea, kaolin, tartaric acid, gelatin, polyvinyl alcohol, dihydroxyaluminum aminoacetate, edetate disodium, methylparaben, and propylparaben.
Indications
LIDOCAN™ is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to
intact skin.
Dosage
Apply
LIDOCAN™ to intact skin to cover the most painful area. Apply the prescribed number of patches (maximum of 3), only once for up to 12 hours within a 24-hour period. Patches may be cut into smaller sizes with scissors prior to removal of the release liner (see HANDLING AND DISPOSAL). Clothing may be worn over the area of application. Smaller areas of treatment are recommended in a debilitated patient, or a patient with impaired elimination.
If irritation or a burning sensation occurs during application, remove the patch(es) and do not reapply until the irritation subsides.
When
LIDOCAN™ is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.
LIDOCAN™ may not stick if it gets wet. Avoid contact with water, such as bathing, swimming, or showering.
Contraindications
LIDOCAN™ is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.
Precautions
Hepatic Disease
Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of lidocaine, because of their inability to metabolize lidocaine normally.
Allergic Reactions
Patients allergic to para-aminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross sensitivity to lidocaine. However,
LIDOCAN™ should be used with caution in patients with a history of drug sensitivities, especially if the etiologic agent is uncertain.
Non-intact Skin
Application to broken or inflamed skin, although not tested, may result in higher blood concentrations of lidocaine from increased absorption.
LIDOCAN™ is only recommended for use on intact skin.
External Heat Sources
Placement of external heat sources, such as heating pads or electric blankets, over lidocaine patch 5% is not recommended as this has not been evaluated and may increase plasma lidocaine levels.
Eye Exposure
The contact of
LIDOCAN™ with eyes, although not studied, should be avoided based on the findings of severe eye irritation with the use of similar products in animals. If eye contact occurs, immediately wash out the eye with water or saline and protect the eye until sensation returns.
Adverse reactions
Drug interactions
Antiarrhythmic Drugs
LIDOCAN™ should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic.
Local Anesthetics When
LIDOCAN™ is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.
Drugs That May Cause Methemoglobinemia When Used with LIDOCAN™
Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics:
Examples of Drugs Associated with Methemoglobinemia:
Class
Example
Nitrates/Nitrites
nitric oxide, nitroglycerin, nitroprusside, nitrous oxide
Local anesthetics
articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine
Antineoplastic agents
cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase
Antibiotics
dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides
Antimalarials
chloroquine, primaquine
Anticonvulsants
Phenobarbital, phenytoin, sodium valproate
Other drugs
acetaminophen, metoclopramide, quinine, sulfasalazine
How supplied
LIDOCAN™ is available as the following:
Carton of 30 patches....................................................................................NDC 5
9088-905-54 (packaged into individual child-resistant envelope)
Single patch............................................................................................. NDC
59088-905-84 (packaged into individual child-resistant envelope)
Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Clinical pharmacology
Lidocaine is an amide-type local anesthetic
agent and is suggested to stabilize neuronal membranes by inhibiting
the ionic fluxes required for the initiation and conduction of impulses.
The penetration of lidocaine into
intact skin after application of a lidocaine patch 5% is sufficient
to produce an analgesic effect, but less than the amount necessary
to produce a complete sensory block.
Clinical studies
Single-dose treatment with lidocaine patch
5% was compared to treatment with vehicle patch (without lidocaine),
and to no treatment (observation only) in a double-blind, crossover
clinical trial with 35 post-herpetic neuralgia patients. Pain intensity
and pain relief scores were evaluated periodically for 12 hours. Lidocaine
patch 5% performed statistically better than vehicle patch in terms
of pain intensity from 4 to 12 hours.
Multiple-dose, two-week treatment with lidocaine
patch 5%, was compared to vehicle patch (without lidocaine) in a double-blind,
crossover clinical trial of withdrawal-type design conducted in 32
patients, who were considered as responders to the open-label use
of lidocaine patch 5% prior to the study. The constant type of pain
was evaluated but not the pain induced by sensory stimuli (dysesthesia).
Statistically significant differences favoring lidocaine patch 5%
were observed in terms of time to exit from the trial (14 versus 3.8
days at p-value <0.001), daily average pain relief, and patient's
preference of treatment. About half of the patients also took oral
medication commonly used in the treatment of post-herpetic neuralgia.
The extent of use of concomitant medication was similar in the two
treatment groups.
1 organization
1 product
Product
Lidocaine 5%Organization
PureTek Corporation